Literature DB >> 225666

Collagenase in the lower respiratory tract of patients with idiopathic pulmonary fibrosis.

J E Gadek, J A Kelman, G Fells, S E Weinberger, A L Horwitz, H Y Reynolds, J D Fulmer, R G Crystal.   

Abstract

To test the hypothesis that idiopathic pulmonary fibrosis (IPF) is mediated through collagenase present in the lower respiratory tract, we used the fiberoptic bronchoscope to obtain fluid from the lower respiratory tract of 24 patients with IPF, 18 controls and nine patients with sarcoidosis. The fluid was analyzed for a variety of enzymes, including collagenase. Fifteen of 21 patients with IPF showed collagenase activity, whereas normal controls and patients with sarcoidosis showed none (P greater than 0.001, for all comparisons). In two patients with IPF who were re-evaluated after eight to 24 months, the collagenase activity was persistent. Fluid from patients with IPF also contained elevated levels of a non-specific neutral protease (P greater than 0.01 compared with controls), but there was no elastase activity in fluid from patients with IPF or from controls. The collagenase found in lavage fluid in IPF cleaved lung collagen into collagenase-specific TCA and TCB fragments. We conclude that in IPF the collagen of the lung is subjected to sustained lysis, followed by disordered resynthesis, and that the presence of active collagenase in the lower respiratory tract is a specific feature of the alveolitis associated with this disease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 225666     DOI: 10.1056/NEJM197910043011401

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  49 in total

1.  Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts.

Authors:  J A Cairns; A F Walls
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

2.  Acute effects of oleic acid-induced lung injury in baboons.

Authors:  J F Collins; R de los Santos; W G Johanson
Journal:  Lung       Date:  1986       Impact factor: 2.584

Review 3.  Lung collagen: more than scaffolding.

Authors:  G J Laurent
Journal:  Thorax       Date:  1986-06       Impact factor: 9.139

Review 4.  Matrix biology of idiopathic pulmonary fibrosis: a workshop report of the national heart, lung, and blood institute.

Authors:  Victor J Thannickal; Craig A Henke; Jeffrey C Horowitz; Paul W Noble; Jesse Roman; Patricia J Sime; Yong Zhou; Rebecca G Wells; Eric S White; Daniel J Tschumperlin
Journal:  Am J Pathol       Date:  2014-04-13       Impact factor: 4.307

5.  Inflammatory responses in lungs of rats inhaling coalmine dust: enhanced proteolysis of fibronectin by bronchoalveolar leukocytes.

Authors:  G M Brown; K Donaldson
Journal:  Br J Ind Med       Date:  1989-12

6.  Mechanisms of neutrophil accumulation in the lungs of patients with idiopathic pulmonary fibrosis.

Authors:  G W Hunninghake; J E Gadek; T J Lawley; R G Crystal
Journal:  J Clin Invest       Date:  1981-07       Impact factor: 14.808

7.  Heterogeneity among human collagenases demonstrated by monoclonal antibody that selectively recognizes and inhibits human neutrophil collagenase.

Authors:  K A Hasty; M S Hibbs; A H Kang; C L Mainardi
Journal:  J Exp Med       Date:  1984-05-01       Impact factor: 14.307

8.  Tissue inhibitor of metalloproteinases and collagenase inhibitory activity in lung secretions from patients with chronic obstructive bronchitis: effect of corticosteroid treatment.

Authors:  D Burnett; J J Reynolds; R V Ward; S C Afford; R A Stockley
Journal:  Thorax       Date:  1986-10       Impact factor: 9.139

Review 9.  New perspectives on basic mechanisms in lung disease. 6. Proteinase imbalance: its role in lung disease.

Authors:  T D Tetley
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

10.  Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema.

Authors:  J E Gadek; G A Fells; R L Zimmerman; S I Rennard; R G Crystal
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.